RTW Investments’s Sagimet Biosciences SGMT Stock Holding History

RTW Investments’s Portfolio SGMT Stock Details SGMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-500,000	Closed	-$1.71M	–	73
2024 Q2	$1.71M	Sell	500,000 -499,147	-50%	-$2.29M	0.03%	64
2024 Q1	$5.42M	Buy	+999,147	New	+$7.18M	0.08%	62
2023 Q4	–	Sell	-400,277	Closed	-$3.52M	–	74
2023 Q3	$3.52M	Buy	+400,277	New	+$5.33M	0.07%	59

Other funds holding SGMT

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

RTW Investments's SGMT Position: Q3 2024 in Review

RTW Investments sold out of Sagimet Biosciences (SGMT) in Q3 2024, closing a stake of 500,000 shares — an estimated $1.71M sold.

RTW Investments first reported a position in SGMT in Q3 2023 and held it in 3 quarters. The position peaked at $5.42M in Q1 2024. 63 funds tracked by Wall St. Rank hold SGMT as of Q3 2024.

RTW Investments reported no remaining Sagimet Biosciences position as of Q3 2024 after selling out during the quarter.
RTW Investments sold 500,000 Sagimet Biosciences shares in Q3 2024, an estimated $1.71M.
RTW Investments first reported a position in Sagimet Biosciences in Q3 2023 and held it in 3 quarters.
RTW Investments's Sagimet Biosciences position peaked at $5.42M in Q1 2024.
63 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q3 2024.

Based on RTW Investments's 13F filing for Q3 2024, filed 14 Nov 2024.